MeSH Browser

MeSH Heading: Benserazide
Tree Number(s): D02.442.175
Unique ID: D001545
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D001545
Scope Note: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
Entry Term(s): DL-Serine 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide; Ro 4-4602; Serazide; Seryltrihydroxy Benzylhydrazine; Seryltrihydroxybenzylhydrazine
Pharm Action: Antiparkinson Agents
Enzyme Inhibitors
Dopamine Agents
Related Numbers: 322-35-0
CAS Type 1 Name: DL-Serine, 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide
Previous Indexing: Benzene (1966-1967); Benzene Derivatives (1968-1971); Benzyl Compounds (1972); Hydrazines (1966-1972); Serine (1966-1972)
Public MeSH Note: 91; was see under HYDRAZINES 1979-90; was SERYLTRIHYDROXY BENZYLHYDRAZINE see under HYDRAZINES 1975-78
Online Note: use BENSERAZIDE to search SERYLTRIHYDROXY BENZYLHYDRAZINE 1973-78 (as Prov 73-74)
History Note: 91(79); was see under HYDRAZINES 1979-90; was SERYLTRIHYDROXY BENZYLHYDRAZINE see under HYDRAZINES 1973-78 (Prov 1973-74)
Date Established: 1991/01/01
Date of Entry: 1999/01/01
Revision Date: 2013/07/08

Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

agonists (AG)

analogs & derivatives (AA)

analysis (AN)

antagonists & inhibitors (AI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

economics (EC)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

urine (UR)

Concept UI: M0002315
Related Numbers: 322-35-0
Scope Note: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
Terms: Benserazide Preferred Term
Term UI T004472
Date01/01/1999
LexicalTag NON
ThesaurusID; DL-Serine 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide
Term UI T004475
Date03/25/1994
LexicalTag NON
ThesaurusID NLM (1995); Serazide
Term UI T004473
Date02/08/1978
LexicalTag NON
ThesaurusID UNK (19XX); Seryltrihydroxy Benzylhydrazine
Term UI T004476
Date02/08/1978
LexicalTag NON
ThesaurusID UNK (19XX); Seryltrihydroxybenzylhydrazine
Term UI T004474
Date02/08/1978
LexicalTag NON
ThesaurusID UNK (19XX)

Benserazide MeSH Descriptor Data 2024